总丙戊酸与游离丙戊酸的PBPK建模:评估伴或不伴低白蛋白血症儿童的给药方案
本研究开发并验证了丙戊酸(VPA)的生理药代动力学(PBPK)模型,模拟总药与游离药浓度。模型成功预测了3-120 mg/kg剂量范围内的非线性药代动力学。在正常白蛋白儿童中,30-45 mg/kg/天的剂量可使总VPA谷浓度落在50-100 mg/L治疗窗内;但低白蛋白血症虚拟儿童大多无法达到目标暴露。
要点
- PBPK模型能预测VPA非线性药代动力学及白蛋白对暴露的影响
- 正常白蛋白儿童30-45 mg/kg/天时总VPA谷浓度在治疗窗内
- 低白蛋白血症儿童即使相同剂量也常无法达到目标暴露
核心结论
- PBPK模型有助于评估VPA的非线性剂量-暴露关系及白蛋白浓度对达标的影响。
研究设计与样本
- 研究首先在成人中建立并评价PBPK模型,再缩放至1岁及以上儿童。
- 采用二阶动力学描述VPA与白蛋白按2:1摩尔比的可饱和蛋白结合。
- 在正常及低白蛋白水平的虚拟人群中开展药代动力学模拟。
主要发现
- 模型充分预测了不同年龄和3-120 mg/kg剂量范围内总VPA和游离VPA的浓度-时间曲线。
- 模型良好预测了浓度依赖的游离分数(fu)及剂量依赖的清除率。
- 正常白蛋白儿童中,30-45 mg/kg/天剂量下模拟的总VPA稳态谷浓度低于剂量比例,且落在50-100 mg/L治疗药物监测范围内。
- 低白蛋白血症虚拟儿童大多未能达到目标暴露。
关键数值与推荐
- 总VPA治疗药物监测范围为50-100 mg/L。
- 在正常白蛋白儿童中,30-45 mg/kg/天剂量可使总VPA谷浓度落在50-100 mg/L范围内。
- VPA与白蛋白的结合按2:1摩尔比的二阶动力学表征。
临床怎么用
- 临床可参考PBPK模型预测结果,在正常白蛋白儿童中30-45 mg/kg/天剂量可能使总VPA谷浓度达标。
- 对低白蛋白血症儿童,应警惕常规剂量下总VPA暴露不足,需结合游离药物浓度监测调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Valproic acid (VPA) demonstrates nonlinear pharmacokinetics (PK) due to a capacity-limited protein binding, which has potential implications on its total and unbound plasma concentrations, especially during hypoalbuminemia. A physiologically based pharmacokinetic (PBPK) model was developed to assess the nonlinear dose-exposure relationship of VPA with special emphasis on pediatric patients with hypoalbuminemia. METHODS: A PBPK model was first developed and evaluated in adults using PK-Sim® and MoBi® (v.11) and the scaled to children 1 year and older. The capacity-limited protein binding was characterized by second-order kinetics between VPA and albumin with a 2:1 molar ratio. All drug-specific parameters were informed by literature and optimized using published PK data of VPA. PK simulations were performed in virtual populations with normal and low albumin levels. RESULTS: The reported concentration-time profiles of total and unbound VPA were adequately predicted by the PBPK model across the age and dose range (3-120 mg/kg). The model was able to characterize the nonlinear PK, as the concentration-dependent fraction unbound (fu) and the related dose-dependent clearance values were well predicted. Simulated steady-state trough concentrations of total VPA were less than dose-proportional and were within the therapeutic drug monitoring range of 50-100 mg/L for doses between 30 and 45 mg/kg per day in children with normal albumin concentrations. However, virtual children with hypoalbuminemia largely failed to achieve the target exposure. CONCLUSION: The PBPK model helped assess the nonlinear dose-exposure relationship of VPA and the impact of albumin concentrations on the achievement of target exposure.
引用
- Karatza E, Sinha J, Maglalang PD, et al. Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia. Clin Pharmacokinet. 2024. PMID: 39298079. doi:10.1007/s40262-024-01418-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。